Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.41 USD
Change Today +0.10 / 1.58%
Volume 153.4K
TNXP On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Open
$6.45
Previous Close
$6.31
Day High
$6.86
Day Low
$6.33
52 Week High
08/26/14 - $15.21
52 Week Low
10/20/14 - $5.33
Market Cap
103.4M
Average Volume 10 Days
91.2K
EPS TTM
$-2.77
Shares Outstanding
16.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TONIX PHARMACEUTICALS HOLDIN (TNXP)

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $277.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.2K
Chief Scientific Officer, Secretary and Contr...
Total Annual Compensation: $238.2K
Compensation as of Fiscal Year 2013.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Pharmaceuticals Holding Corp Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Tonix Pharmaceuticals Holding Corp. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported operating loss of $9,004,000 against $3,709,000 a year ago. Net loss was $8,989,000 or $0.83 per basic and diluted share against $3,707,000 or $0.74 per basic and diluted share a year ago. For the year, the company reported operating loss of $27,656,000 against $10,888,000 a year ago. Net loss was $27,616,000 or $2.77 per basic and diluted share against $10,884,000 or $3.37 per basic and diluted share a year ago.

Tonix Pharmaceuticals Holding Corp Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015

Tonix Pharmaceuticals Holding Corp Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Presentation Date & Speakers: Mar-03-2015, Seth Lederman, Co-Founder, Chairman, Chief Executive Officer and President.

Tonix Eyes Acquisitions

Tonix Pharmaceuticals Holding Corp (NasdaqGM:TNXP) is looking for acquisition opportunities. Tonix intends to offer shares of its common stock in an underwritten public offering. Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL for the management of fibromyalgia and post-traumatic stress disorder, to support the continued development of TNX-201 for the treatment of episodic tension-type headache, to further develop our other pipeline programs, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $6.41 USD +0.10

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies
 

Industry Analysis

TNXP

Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONIX PHARMACEUTICALS HOLDIN, please visit www.tonixpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.